Abstract
Background: This study aimed to: (1) Investigate some clinical and paraclinical characteristics in patients with pancreatic cancer. (2) Investigate associations of clinical, paraclinical characteristics with tumor characteristics, and with pancreatic cancer stages according to the TNM classification.
Materials and method: The study was conducted on a convenience sample size of 50 patients diagnosed pancreatic cancer by histopathology.
Results: The mean age was 64.3 ± 11.1 years, 56.0% of them were female. Diabetes mellitus and overweight, obesity accounted for a high proportion of 32.0% and 28.0%, respectively. The predominant symptom was abdominal pain (98.0% of cases). CA 19-9 levels were elevated in 76.0% of patients. Most patients were in stage III and IV of the TNM classification, accounting for 36.0% each. The most common histological type was adenocarcinoma, accounting for 98.0% of cases. The tumor location was mainly in the head of the pancreas with 66.0%. There was an association between pancreatic head tumors and jaundice. Multivariate regression analysis revealed a significant association between CA 19-9 levels and TNM stages (OR = 1.303, p = 0.022, 95% CI: 1.038 - 1.636).
Conclusion: Adenocarcinoma was the most prevalent. History of diabetes and overweight,obesity accounts for a high proportion. Tumors in thepancreatic head were themost frequently observed. Abdominal pain is a common symptom. CA 19-9 levels were elevated in 76.0% of patients and associated with TNM stages.
| Published | 2025-09-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 5 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.5.12 | |
| Keywords | ung thư tụy, CA 19-9, CEA, TNM, ECOG pancreatic cancer, CA 19-9, CEA, TNM, ECOG |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
Trần Văn Huy. Giáo trình sau đại học Bệnh học gan mật tụy. Huế: Nhà xuất bản Đại học Huế. 2017.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Wangermez M. Endoscopic ultrasound of pancreatic tumors. Diagn Interv Imaging 2016;97:1287–95.
Lê Thanh Đức, Bùi Thành Lập. Đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư tụy giai đoạn tiến triển, di căn tại Bệnh viện K. Tạp chí Y học Việt Nam. 2023;524:911–5.
Trịnh Phạm Mỹ Lệ, Hồ Đăng Quý Dũng, Trần Văn Huy. Nghiên cứu một số đặc điểm lâm sàng, sinh học và siêu âm nội soi ở bệnh nhân ung thư tụy tại Bệnh viện Chợ Rẫy. Tạp chí Y Dược Huế. 2021;11:60–5.
Nguyễn Thành Lam, Vi Trần Doanh, Trần Bảo Ngọc, Hoàng Minh Tú, Lê Duy Sơn. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư tụy tại Trung tâm Ung bướu Thái Nguyên. Tạp chí Y học Lâm sàng - Bệnh viện Trung ương Huế. 2022;82:111–8.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.
Sanjay Kakar, Timothy M. Pawlik, Peter J. Allen, Jean-Nicolas Vauthey. Exocrine Pancreas. In: Mahul B. Amin, Stephen B. Edge, Frederick L. Greene, David R. Byrd, Robert K. Brookland, Mary Kay Washington, et al., editors. AJCC Cancer Staging Manual. Springer. 2017. page 337–47.
Ko SW, Kim TH, Song TJ, Kim SH, Seo DW, Yoon JH, et al. Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed Tomography. Gut Liver. 2022;16:474–82.
Luo YG, Wu M, Chen HG. Retrospective analysis of pathological types and imaging features in pancreatic cancer: A comprehensive study. World J Gastrointest Oncol. 2025;17:99153.
Grigorescu RR, Husar-Sburlan IA, Gheorghe C. Pancreatic Cancer: A Review of Risk Factors. Life. 2024;14:980.
Gehrels AM, Wagner AD, Besselink MG, Verhoeven RHA, van Eijck CHJ, van Laarhoven HWM, et al. Gender differences in tumor characteristics, treatment allocation and survival in stage I–III pancreatic cancer: a nationwide study. Eur J Cancer. 2024;206:114117.
Abboud Y, Samaan JS, Oh J, Jiang Y, Randhawa N, Lew D, et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology 2023;164:978-989.e6.
Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, et al. Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers. JAMA. 2005;294:2872–8.
Giovannucci E, Michaud D. The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas. Gastroenterology. 2007;132:2208–25.
Park BK, Seo JH, Chung JB, Choi JK. Lifestyle, body mass index, diabetes, and the risk of pancreatic cancer in a nationwide population-based cohort study with 7.4 million Korean subjects. British Journal of Cancer. 2022 127:3 2022;127:549–57.
Huang BZ, Pandol SJ, Jeon CY, Chari ST, Sugar CA, Chao CR, et al. New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population. Clinical Gastroenterology and Hepatology. 2020;18:1812-1821.e7.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021;19:439–57.
Nguyễn Trường Sơn. Nghiên cứu giá trị siêu âm nội soi và chọc hút bằng kim nhỏ trong chẩn đoán ung thư tụy. [Luận án Tiến sĩ Y học], Trường Đại học Y Hà Nội. 2017.
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, et al. Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma. Yonsei Med J. 2013;54:643–9.
Porta M, Fabregat X, Malats N, Guarner L, Carrato A, De Miguel A, et al. Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage. Clinical and Translational Oncology. 2005;7:189–97.
Hu JX, Lin YY, Zhao CF, Chen WB, Liu QC, Li QW, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27:4298–321.
Meslar E. Pancreatic adenocarcinoma. JAAPA. 2020;33:50–1.
Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, et al. Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single Institution. PLoS One. 2013;8:e78977.
Ermiah E, Eddfair M, Abdulrahman O, Elfagieh M, Jebriel A, Al‑Sharif M, et al. Prognostic value of serum CEA and CA19‑9 levels in pancreatic ductal adenocarcinoma. Mol Clin Oncol. 2022;17:126.